Advertisement
UK markets close in 2 hours 57 minutes
  • FTSE 100

    8,103.69
    +63.31 (+0.79%)
     
  • FTSE 250

    19,743.29
    +23.92 (+0.12%)
     
  • AIM

    755.74
    +1.05 (+0.14%)
     
  • GBP/EUR

    1.1658
    +0.0013 (+0.11%)
     
  • GBP/USD

    1.2484
    +0.0021 (+0.17%)
     
  • Bitcoin GBP

    51,328.93
    -1,998.25 (-3.75%)
     
  • CMC Crypto 200

    1,362.96
    -19.61 (-1.42%)
     
  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     
  • DOW

    38,460.92
    -42.77 (-0.11%)
     
  • CRUDE OIL

    83.28
    +0.47 (+0.57%)
     
  • GOLD FUTURES

    2,338.90
    +0.50 (+0.02%)
     
  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     
  • HANG SENG

    17,284.54
    +83.27 (+0.48%)
     
  • DAX

    18,009.52
    -79.18 (-0.44%)
     
  • CAC 40

    8,028.65
    -63.21 (-0.78%)
     

FMC expects NxStage deal to close in next couple of days

Rice Powell, CEO of Fresenius Medical Care, addresses the media during the company's annual news conference at their head quarters in Bad Homburg Germany, February 20, 2019. REUTERS/Kai Pfaffenbach

BERLIN (Reuters) - Germany's Fresenius Medical Care (FMC) said on Wednesday it has won the green light from U.S. regulators to acquire U.S. home dialysis equipment maker NxStage and expects the deal to close in the next few days.

FMC agreed to buy NxStage in August 2017 for $2 billion but the deal has been held up due to competition concerns and most recently the U.S. government shutdown.

"Very early this morning, we were notified the Federal Trade Commission has approved our NxStage deal," Chief Executive Rice Powell told reporters. "We would anticipate closing the NxStage deal over the next couple of days."

FMC's Chief Financial Officer Michael Brosnan also announced he planned to retire once a successor has been identified. FMC said it expects to name a new CFO by the end of the year.

(Reporting by Caroline Copley; editing by Thomas Seythal)